Thank you for Subscribing to Life Science Review Weekly Brief
For decades, biotech has focused on the manipulation of living organisms. Never before, though, has a science-based sector faced such unique challenges as in the twenty-first century. The industry was established in 1970’s during an era of bipartisan cooperation and growth in wealth across the country. Today, despite unprecedented technological advancements in biology, chemistry, and digital health, plus an enormous amount of available capital, the industry is facing serious challenges that threaten its continued existence. Among these challenges are the declining public perception of the pharmaceutical industry, the unprecedented pressure from consolidation, and legislative challenges.
The public perception of the pharmaceutical industry has tanked in the past decade and is now ranked worse than the tobacco industry among some groups. Statements in the media about the industry have had a direct correlation on the NBI biotechnology stock index.
Further, time is the major obstacle for the invention of a new product or a novel product from basic concepts. The time taken for an idea to be proved, prototyped and developed into beneficial invention also determines the success of the product as there are multiple competitors existing in the market. The market is the influence of the success of the product. The product should satisfy the needs of the customer and meet current needs of technology. Technology is the base for building a product. Technology skills sets determine the quality of the product. Skills required to study and develop a new product is important Skilled people are in high demand for their knowledge and hands-on expertise. Funding plays a crucial role in bringing the invention from labs to the market users Its role is an essential part of each footstep of a developing product, throughout their life cycle. This indirectly determines the timeline of the product.
Biotechnology is still in its infancy to find the answers of nature, understand the power beyond science, such as hydrogen and oxygen giving us water. Biotechnology has its own advantage and disadvantage Biotechnologists must be able to handle the society and address the controversial aspects of bringing a technology or a product in use. In conclusion, Biotechnology is a great area but requires time, funding and above all skills.
We present to you, “10 Leading Biotech Solution Providers - 2021.”
Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, they apply their scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease
The key to enabling low production costs, consistency, and easy scale-up in the life sciences sector lies in the adoption of newage innovations that hold the potential to redefine the existing landscape. Accordingly, the adoption of plant biologics in the pharmaceutical space has increased due to the vast benefits it brings. One company that has been redefining the status quo of the life sciences industry is Anovora. The firm’s Big Data platform is directly aimed at Helping companies collect, analyze, and derive meaningful results from data to power research, development, and production of a wide variety of commercial products
Eliza Charles, M.D., and Co-founderWith innovative business solutions that scale for the enterprise, we provide subject matter expertise to our clients
Zea Biosciences is at the forefront of revolutionizing the pharmaceutical space by cutting manufacturing costs and accelerating R&D with affordable, accessible, and scalable plant-based medicines. The company is a leading producer of plant-based biologics based in Walpole, MA. Its proprietary Lighthouse platform enables researchers to grow, optimize minimum-variation plants for use in pharmaceuticals and nutraceuticals. Zea is on the mission to push the boundaries of drug development and unlock the potential of plant biologics by providing access to affordable medicines and inspiring healthier communities
Zea Biosciences Corp
Management
Jim Wilson, CEO
David Neafus, CFO, Charles Legg, COO, Jane Lalonde, CMO
Altasciences is a forward-thinking, mid-size CRO/CDMO offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. They remain steadfast to their original mission—to bring new treatments to market that will make a big impact on small patient populations. The company's product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates
BrightInsight provides the leading global regulated digital health platform for biopharma and medtech. Their medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. At BrightInsight, their vision is to transform patient outcomes globally by bringing the power of digital technology to healthcare
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. They are committed to the relentless pursuit of science that can improve the lives of patients. Their unique expertise in medicinal chemistry and biology has enabled them to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. They are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity
MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials
Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using their VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. By providing DNA Variant libraries and High-Throughput cell assays they can help researchers to hit their research objectives faster and with better results than traditional methods
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, their unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in their laboratories. Their medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases
Regeneron Pharmaceuticals
Management
Leonard S. Schleifer, Founder, President and CEO